| HS Code | 285688 |
| Product Name | Goat Pox Vaccine, Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Vaccine Type | Live attenuated viral vaccine |
| Pathogen | Goatpox virus (family Poxviridae, genus Capripoxvirus) |
| Veterinary Grade | Yes |
| Api Form | Bulk veterinary-grade active pharmaceutical ingredient |
| Target Species | Goats |
| Target Disease | Goat pox (contagious ecthyma / capripox) |
| Compatible Dosage Forms | Tablets, injections, capsules, powders, granules, premix, and solutions |
| Route Of Administration | Injectable formulation; other routes per downstream formulation |
| Protective Mechanism | Induces humoral and cell-mediated immune response against goatpox virus |
| Onset Of Immunity | Within 10 to 14 days after vaccination |
| Duration Of Immunity | Generally 12 months or longer depending on formulation |
| Storage Conditions | 2°C to 8°C, protected from light and freezing |
| Shelf Life | Typically 18 to 24 months from date of manufacture |
| Bioburden Control | Produced under aseptic veterinary-grade conditions |
| Adjuvant Compatibility | Compatible with standard veterinary vaccine stabilizers |
| Administration Frequency | Usually single dose with periodic revaccination |
| Post Vaccination Reaction | May cause mild transient fever or local swelling |
| Withdrawal Period | Zero days for meat when used per label in veterinary dosing |
As an accredited Goat Pox Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Each carton contains 100 x 10-dose glass vials of lyophilized Goat Pox Vaccine, Live, veterinary grade API. |
| Container Loading (20′ FCL) | Packed in temperature-controlled 20′ FCL with cold-chain gel packs, palletized and sealed, ensuring stability of live veterinary vaccine formulations. |
| Shipping | Shipped under strict cold-chain conditions at 2–8°C in insulated containers with approved gel packs and temperature loggers. Tamper-evident, leak-proof packaging prevents contamination. Labeled as Live Veterinary Vaccine. Expedited air freight with full customs/regulatory documentation. Protect from freezing, heat, and direct sunlight during transit. |
| Storage | Store at 2–8°C (refrigerate) and protect from light. Do not freeze. Keep in original, tightly sealed containers under dry conditions. Avoid exposure to heat, direct sunlight, or oxidizing agents. Handle aseptically to preserve vaccine potency. Ensure proper cold-chain transport and monitor temperature continuously. Use within recommended shelf life after first opening. |
| Shelf Life | Shelf life: 24 months when stored refrigerated at 2–8°C, protected from light and not frozen. |
The live attenuated capripoxvirus API for goat pox prophylaxis is received at the downstream formulation site as a frozen virus concentrate or as a formulated lyophilisation intermediate whose infectivity titre is specified in TCID50 per millilitre. A manufacturer preparing a monovalent injection must first thaw the bulk concentrate at 2–8°C or 37°C in a controlled water bath, pool single-use bags, and clarify the suspension by differential centrifugation at 1,500–3,000 × g for 10–20 min to remove cell debris. The formulation addition ratio at this stage is typically a 1:1 v/v dilution of the clarified virus suspension with a double-strength stabiliser solution composed of 2–10% w/v sucrose, 1–5% w/v gelatin, and 0.5–3% w/v lactalbumin hydrolysate, so that the final stabiliser concentration falls within the range shown to protect capripoxvirus infectivity during freezing and drying. Because capripoxvirus virions are approximately 250–300 nm, sterile filtration through 0.22 µm membranes is not applicable; the entire formulation train is operated as an aseptic process under ISO 13408-1:2008 and requires environmental monitoring for viable and non-viable particulates. The downstream production process involves chilled stainless steel or single-use mixing vessels maintained at 2–8°C, continuous low-shear mixing at 50–100 rpm, and filling into Type I borosilicate glass vials with bromobutyl stoppers under nitrogen overlay if validated. Sterility and mycoplasma release testing are performed in accordance with Ph. Eur. 2.6.1 and Ph. Eur. 2.6.7, with identity and potency evaluated against the OIE Terrestrial Manual chapter for capripoxvirus infections. The end product type is a sterile live viral suspension filled as the pre-lyophilisation liquid format, which is immediately transferred to the freeze dryer under controlled temperature hold time not exceeding 8 h to minimise viral titre decay.
| Stabiliser component | Final concentration range | Function | Critical failure mode above range |
|---|---|---|---|
| Sucrose | 2–10% w/v | lyoprotectant, vitrification agent | elevated collapse temperature shifts the primary drying boundary |
| Gelatin | 1–5% w/v | protein cryoprotectant, thermal stabiliser | high viscosity slows aseptic filling precision |
| Lactalbumin hydrolysate | 0.5–3% w/v | protein hydrolysate stabiliser | residual moisture variability in finished cake |
Tablet, capsule, granule, and premix presentations are excluded from the live capripoxvirus application matrix because poxvirus particles are not compatible with dry compression or with the low pH environment of oral administration. Published data for this specific configuration is limited, and current regulatory precedent restricts the live goat pox API to injectable lyophilised presentations.
The lyophilisation process for live goat pox vaccine is constrained by two competing failure modes: cake collapse at excessively high shelf temperature and viral inactivation caused by prolonged primary drying or incomplete secondary drying. The formulated suspension entering the freeze dryer typically carries 8–15% w/v total solids, with the dried cake mass fraction distributed as 60–80% w/w sucrose and gelatin as lyoprotectants, 10–25% w/w bulking agents such as mannitol or glycine, and 10–20% w/w buffer salts. The freeze-drying programme begins with shelf cooling to −40°C to −50°C at a controlled ramp of 0.5–1.0°C/min, followed by an annealing step at −20°C for 2–4 h to allow crystallisation of any mannitol and to reduce subambient heterogeneity. Primary drying is maintained at a shelf temperature of −25°C to −15°C and chamber pressure 50–100 µbar for 12–24 h, with product temperature monitored by thermocouples and kept below the collapse temperature determined by freeze-drying microscopy. Secondary drying is then performed at 20°C for 4–6 h until residual moisture by coulometric Karl Fischer titration meets the release limit of ≤2.0% w/w under Ph. Eur. 2.6.32. Batch failures observed on production-scale lyophilisers equipped with shelf areas above 5 m² are most frequently associated with edge-vial overheating during secondary drying and with door-opening interventions that introduce moisture; therefore, cycle control must include continuous chamber dew point data and pressure rise testing. The compliance standards for the finished lyophilised injection are Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, and Ph. Eur. 2.6.7 for mycoplasma. The end product type is a lyophilised plug in a Type I glass vial sealed under inert gas with a bromobutyl stopper, intended for reconstitution immediately before subcutaneous administration.
| Lyophilisation phase | Shelf temperature range | Chamber pressure | Duration | Control variable |
|---|---|---|---|---|
| Freezing | −40°C to −50°C | atmospheric | 2–4 h | ramp rate 0.5–1.0°C/min |
| Annealing | −20°C | atmospheric | 2–4 h | crystallisation completion |
| Primary drying | −25°C to −15°C | 50–100 µbar | 12–24 h | product temperature below collapse |
| Secondary drying | 20°C | 50–100 µbar | 4–6 h | residual moisture ≤2.0% w/w |
For the sterile diluent used to reconstitute lyophilised goat pox vaccine, the manufacturing process is defined by the need to avoid hypertonic shock and to maintain the colloidal stability of the capripoxvirus particles after rehydration. A common composition is a phosphate-buffered saline solution containing 0.80% w/v sodium chloride, 0.02% w/v potassium chloride, 0.115% w/v disodium hydrogen phosphate, and 0.02% w/v potassium dihydrogen phosphate, adjusted to pH 7.0–7.4 with 0.1 M hydrochloric acid or sodium hydroxide. The addition ratio for the buffer salts is fixed at this ionic strength to produce an osmolality below 300 mOsm/kg; deviations above this threshold have been associated with aggregation and titre loss in related live veterinary viral vaccines, although published data for goat pox diluent configurations is limited. The production process for the diluent consists of dissolution at 20–25°C in water for injection, pre-filtration through 0.45 µm membranes, sterile filtration through 0.22 µm membranes, and filling into LDPE ampoules or glass vials. Terminal sterilisation by autoclaving at 121°C for 15 min is applied only when the container material and headspace allow; if terminal sterilisation is not used, the diluent is aseptically filled under ISO 13408-1:2008 and released according to Ph. Eur. 2.6.1 and Ph. Eur. 2.6.14. The end product type is a sterile, endotoxin-controlled diluent intended for single-use reconstitution of the lyophilised vaccine vial.
During campaign production, frozen bulk live capripoxvirus antigen is often supplied with a cryoprotectant system containing 10% v/v dimethyl sulfoxide or 5% v/v glycerol because cell-free virus stocks undergo severe titre loss during uncontrolled freezing. The downstream processor must thaw the frozen bulk at 37°C in a validated water bath with agitation until the last ice disappears, then immediately transfer the container to a 2–8°C cold hold. The formulation addition ratio after thawing is a 1:10 v/v dilution into chilled stabiliser solution, which reduces residual dimethyl sulfoxide to ≤1.0% v/v or residual glycerol to ≤0.5% v/v in the final filling suspension, consistent with typical injectable limits for organic solvent residuals. Repeated freeze-thaw cycles must be avoided because the 250–300 nm capripoxvirus particle is sensitive to ice recrystallisation and because re-freezing after thaw shifts the titre by 0.5–1.0 log10 TCID50/mL per cycle in observed production campaigns; this figure is derived from site-specific trend data and should be confirmed with process validation. The downstream process is carried out in closed single-use systems to prevent cross contamination and to reduce exposure to ambient carbon dioxide, which can depress pH in bicarbonate-containing stabilisers. Compliance standards include Ph. Eur. 2.6.1 for the downstream sterile hold and ICH Q5A(R2) guidance for viral safety of biological products; identity testing remains aligned to the OIE Terrestrial Manual chapter for capripoxvirus infections. The end product type for this scenario is a thawed, diluted live viral suspension ready for aseptic filling and lyophilisation.
In field cold-chain conditions, the reconstitution of lyophilised goat pox vaccine must be controlled to prevent microbial ingress and thermal degradation of the live attenuated virus. The registration-defined reconstitution ratio for a monovalent goat pox vaccine vial is typically expressed as 1 part lyophilised cake to 10 parts sterile diluent, though the exact dose volume and virus titre per dose are fixed by the product registration and are not adjustable at the point of use. The diluent is introduced through a vented transfer device or a sterile needle into the vaccine vial, and the suspension is mixed by gentle swirling at 2–8°C; vortexing or high-shear agitation is avoided because cavitation may damage the poxvirus envelope. After reconstitution, the suspension must be held at 2–8°C and used within the label-defined window, commonly 4–6 h, because the stabiliser matrix becomes diluted and viral titre decay accelerates above 8°C. Injection equipment for subcutaneous administration is typically a 0.5–1.0 mL syringe with a 25–27 G needle, and the suspension is drawn without silicone oil interaction validation if the syringe type differs from the registration stability studies. The relevant compliance standards are Ph. Eur. 2.6.1 for the diluent sterility, Ph. Eur. 2.6.14 for endotoxin control, and the OIE Terrestrial Manual chapter for capripoxvirus infections for post-reconstitution potency. The end product type is a ready-to-inject live viral suspension for subcutaneous administration in goats.
Competitive Goat Pox Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Goat Pox Vaccine, Live, Veterinary Grade API is a cell-culture-adapted live attenuated capripoxvirus bulk antigen intended for downstream pharmaceutical formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The material is not a finished vaccine presentation; it is supplied as a freeze-dried or frozen suspension and requires further manufacture in a licensed veterinary pharmaceutical facility before administration. The active-fraction identity is confirmed against a characterized master seed lot by capripoxvirus-specific real-time polymerase chain reaction or virus neutralization. The bulk product designation is commonly reported as GPV-LIVE-API-BULK/
Each batch is assigned a virus titre after propagation on primary goat/lamb testis or Vero cells and is released only after sterility, mycoplasma, identity, pH, stabilizer concentration, and moisture tests are completed. The titre is reported as log₁₀ TCID₅₀ per millilitre or per milligram of lyophilized powder; downstream manufacturers use this value to calculate the excipient-to-virus ratio required for a target final dose. Because the live viral particle is sensitive to temperature, humidity, shear, and organic solvents, the API cannot be treated as a conventional small-molecule active ingredient. Receiving facilities are expected to maintain 2–8 °C cold-chain for liquid suspensions or ≤ −20 °C for long-term lyophilized storage, with freeze-thaw cycles limited to no more than 3 cycles per validation protocol.
Specifications are aligned with the relevant sections of the WOAH Terrestrial Manual chapter for capripoxvirus diseases and the general chapters of the European Pharmacopoeia for live viral veterinary antigens. The table below summarizes a representative release matrix for the bulk API; exact values are lot-specific and are issued on the certificate of analysis. Absence of a harmonized monograph for goat pox bulk means that receiving manufacturers must correlate in-house tests with master seed qualification and downstream titre recovery.
| Parameter | Reference method | Representative release target |
|---|---|---|
| Bulk lyophilized moisture | Karl Fischer coulometry; Ph. Eur. 2.5.12 | ≤ 3.0% w/w |
| Bulk virus titre after reconstitution | Cell culture titration; WOAH Terrestrial Manual chapter for capripox | not less than 10³·⁵ TCID₅₀ per final dose equivalent |
| Sterility | Membrane filtration / direct inoculation; Ph. Eur. 2.6.1 | no growth after 14 days |
| Mycoplasma | Agar and broth culture plus indicator cell DNA stain; Ph. Eur. 2.6.7 | not detected |
| pH of bulk suspension | Potentiometry; Ph. Eur. 2.2.3 | 6.5–7.5 |
| Bulk water activity before tableting or encapsulation | Dew-point water activity meter | below 0.3 |
In downstream processing, the freeze-dried bulk is generally equilibrated in a GMP suite classified at least ISO 14644-1 Class 8. For tablet and capsule manufacture, the lyoprotectant matrix is the principal determinant of virus survival because direct compression generates localized mechanical and thermal stress. A sucrose-trehalose glass matrix with residual moisture controlled below 3.0% w/w is commonly used for heat-labile live virus powders; published formulation data specific to goat pox virus tablet compression are limited, so each compression profile must be validated by titre recovery and infectivity assay. When dry granulation is applied, slugging pressure is constrained to avoid press temperature excursions above 30 °C, and the granulated intermediate is stored in sealed aluminium-laminated sachets with desiccant. Aqueous granulation is discouraged unless a low-temperature fluid-bed dryer can maintain product temperature below 25 °C and outlet air below 30% relative humidity. Direct compression is preferred when the API particle size distribution permits adequate blend uniformity without excessive compression force.
Preblend operations on production-scale V-blenders and bin blenders have shown that charged live-virus powders segregate when fill volume falls below 30% of rated capacity; geometric dilutions in two or more staged passes are therefore used before final blend discharge. Operators report that high-shear granulation above 10,000 rpm can reduce titre by thermal and mechanical disruption, although published data for goat pox virus at production scale are limited. Low-shear mixing and gentle tumble blending are therefore selected for initial formulation work unless stability data demonstrate otherwise.
Tablet compaction exposes the API to pressure, frictional heating, and excipient surface interactions. The operational boundary for live goat pox virus in direct compression is usually set by press speed and compression force rather than by punch temperature alone; compaction forces above 7 kN on a single-punch instrumented press may be detrimental if the powder bed temperature exceeds 27–30 °C. However, no globally accepted force limit exists for goat pox virus tablets, and published data for this specific configuration are limited. Formulators therefore establish a design space by measuring virus titre as a function of compression force, press dwell time, and tablet hardness. Tablet hardness is minimized to the lowest value that still meets pharmacopoeial friability requirements; a common acceptance is ≤ 1.0% friability after 100 rotations in a USP friabilator. Excipients that generate alkaline microenvironments or residual peroxides are avoided because they accelerate viral envelope damage.
For injectable solutions, the lyophilized API is reconstituted aseptically in water for injection containing the designated stabilizer. The reconstituted bulk is held at 2–8 °C and used within 4 h unless the manufacturer’s validation demonstrates longer stability. High-shear mixing, sonication, pH outside 6.5–7.5, and preservatives such as thimerosal or benzalkonium chloride are considered incompatible unless compatibility is demonstrated by titre recovery. Because the API is a live enveloped virus, sterile filtration through 0.22 µm membranes is generally not suitable; the product is supplied sterile by aseptic processing rather than terminal filtration.
Powders, granules, and premixes intended for feed or water delivery require a lyoprotectant matrix compatible with feed components. Vitamin and mineral premixes containing free copper or oxidizing agents are avoided because free radical generation may inactivate the virus. Packaging is flushed with nitrogen or vacuum-sealed to limit oxidative damage to the viral envelope. Lactose-based granules may be suitable if amorphous lactose content is controlled and if the final blend water activity remains below 0.3. Hard gelatin capsules may be filled directly with lyophilized API and dried diluents; capsule filling machines must operate at low humidity and with reduced tamping force because mechanical shear on the filling turret can generate heat. Enteric release coatings are not standard for live goat pox virus capsules; if used, the coating process temperature and solvent level must be validated for virus survival, and published data for this configuration remain limited.
This product is a live attenuated capripoxvirus bulk, while inactivated goat pox vaccines contain chemically or physically inactivated whole virus or subunit fractions. The live bulk typically requires a much lower antigen mass per dose and can induce cell-mediated and mucosal immune responses without the addition of mineral oil or other adjuvants; however, live virus dosage forms are thermolabile and require containment during manufacture. Inactivated capripox preparations are more tolerant of ambient handling and can be formulated with adjuvants, but published comparative efficacy data for goat pox vaccines indicate that inactivated products generally require higher antigen payloads or booster administration to achieve equivalent protection. The present API is also not a ready-to-use vialled vaccine: it does not include final diluent, route-specific labelling, or approved package insert, and it must not be administered directly to animals.
| Attribute | Live goat pox API | Inactivated goat pox antigen | Finished vialled goat pox vaccine |
|---|---|---|---|
| Replicative state | Attenuated replication-competent virus | Non-replicating antigen | Live or inactivated as registered |
| Heat sensitivity | High; cold chain required | Moderate; adjuvant-dependent | Formulation-dependent |
| Route of use | Further manufacturing only | Further manufacturing only | Direct veterinary administration |
| Primary release parameter | Virus titre in log₁₀ TCID₅₀ | Antigen mass / adjuvant concentration | Final dose content and safety |
Within the capripoxvirus genus, goat pox virus is closely related to sheeppox and lumpy skin disease viruses. The live API should not be automatically substituted for a sheeppox or lumpy skin disease API on the basis of phylogenetic relatedness alone. Cross-protection studies have been published for capripox species, but regulatory claims are species-specific and the receiving manufacturer must file the final product with the intended species and route of administration. A manufacturer preparing a different capripox presentation must demonstrate identity, purity, safety, and efficacy according to national registration requirements and the applicable WOAH chapter.
The intended use of the finished dosage forms is active immunization of goats against goat pox; capsule, tablet, and premix presentations may be developed for mucosal or oral antigen delivery where regional regulatory authorities accept such routes. Published data for oral tablet and premix administration of live goat pox virus are limited, so most licensed presentations remain injectable lyophilized preparations. In all cases, the finished product is dosed on the basis of virus titre rather than bulk powder weight, because lyophilization can generate batch-to-batch titre variation of approximately ± 0.5 log₁₀. This requirement contrasts with chemical veterinary APIs, where active content is expressed as a gravimetric or chromatographic assay value.
Stability of the API is formulation-specific. Bulk lyophilized material stored at −20 °C is generally assigned a shelf life of 24 months when protected from light and humidity; frozen liquid bulk at 2–8 °C is limited to short holding times. Residual moisture above 3.0% w/w accelerates titre decline, and repeated exposure to ambient humidity during tableting or encapsulation is a known batch-failure mode. The receiving manufacturer is therefore required to perform a stability-indicating titre assay on each incoming lot and after any extended hold. This operational boundary is based on general live viral vaccine behavior, and product-specific data remain limited for non-parenteral goat pox formulations.
